Gabather reports initial positive results from the EEG/fMRI target engagement study
STOCKHOLM, March 7, 2024 -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather´s GABA\A\-receptor positive allosteric modulator, GT-002, in healthy volunteers.The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002. The secondary objective to demonstrate target engagement in human brain was also met. The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels